| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6221392 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6024981 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Fluxid is owned by Ucb Inc.
Fluxid contains Famotidine.
Fluxid has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Fluxid are:
- US6221392
- US6024981
Fluxid was authorised for market use on 24 September, 2004.
Fluxid is available in tablet, orally disintegrating;oral dosage forms.
The generics of Fluxid are possible to be released after 09 April, 2018.
Drugs and Companies using FAMOTIDINE ingredient
Market Authorisation Date: 24 September, 2004
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
FLUXID family patents
